Orion

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES BOARD / MANAGEMENT / AUDITORS7 July 2023 at 14.30 EEST Orion Corporation: Change in Orion Group Executive Management Board as of 30 April 2024 Jari Karlson, the Chief Financial Officer of the Orion Group and member of the Executive Management Board of the Orion Group has announced that he will step down from his position at Orion as of 30 April 2024 and that he will retire. He has worked in his current position since 2002. Orion has started the recruiting process of the successor of Jari Karlson. Karlson will continue in his current position and as a member of the Executive Management Board of the Orion Group until 30 April 2024. Orion Corporation Liisa Hurme President and CEO Olli Huotari SVP, Corporate Functions Contact person:Liisa Hurme, President and CEOtel. +358 10 426 2874 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE28 APRIL 2023 at 11.30 EEST Composition of the Nomination Committee of Orion Corporation The Board of Directors of Orion Corporation has appointed the following persons to the Nomination Committee of the company: Annika EkmanPetteri KarttunenMinna MaasiltaHilpi RautelinSeppo SalonenMikael Silvennoinen Mikael Silvennoinen was appointed as Chair of the Committee. The Committee prepares and presents a recommendation to the Board of Directors for the proposal to the Annual General Meeting concerning the composition of the Board. The essentials of the charter of the Nomination Committee and a description of the appointment process of its members are provided at https://www.orion.fi/en/investors/corporate-governance/board-of-directors/nomination-committee/charter-of-the-nomination-committee/, a page in the Corporate Governance section of the Orion Group website. Orion Corporation Liisa HurmePresident and CEO Olli HuotariSVP, Corporate Functions Contact person:Olli Huotari, SVP, Corporate Functions, Secretary to the Board of Directors of Orion Corporationtel. +358 10 426 3054 Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

STOCK EXCHANGE RELEASE / CHANGES IN COMPANY’S OWN SHARES 1 MARCH 2023 at 20.30 EET Orion Corporation: Transfer of 149,798 own B shares on 1 March 2023 In accordance with a decision by the Board of Directors, Orion Corporation has on 1 March 2023 transferred altogether 149,798 Orion Corporation B shares held by the company as a share reward for earning period 2020–2022 to the persons belonging to the Share-based Incentive Plan of the Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 23 March 2022. The price per share of the transferred shares is EUR 44.2606, which is the volume weighted average quotation of the Orion Corporation B share on 1 March 2023. Accordingly, the total transaction price of the transferred shares is EUR 6,630,149.36. After the share transfer, the total number of own B shares held by Orion Corporation is 782,973. Orion Corporation has informed about the Share-based Incentive Plan in stock exchange release on 6 February 2019. Orion Corporation Liisa Hurme President and CEO Olli Huotari SVP, Corporate Functions Contact person: Olli Huotari, SVP, Corporate Functions, tel. +358 10 426 3054, mobile +358 50 966 3054 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland http://www.orion.fi/en http://www.twitter.com/OrionCorpIR Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.